Drug interactions with fibric acids

Ahmad, 1990, Gemfibrozil interaction with warfarin sodium (coumadin), Chest, 98, 1041, 10.1378/chest.98.4.1041b Ahmad, 1991, Gemfibrozil: interaction with glyburide (letter), South. Med. J., 84, 102, 10.1097/00007611-199101000-00027 American Medical Association, 1992, Agents used to treat hyperlipidemia Aoyama, 1990, Clofibrate-inducible rat hepatic P450s IVA1 and IVA3 catalyze the w-and (w-1) hydroxylation of fatty acids and the w-hydroxylation of prostaglandins E1 and F2ol, J. Lipid Res., 31, 1477, 10.1016/S0022-2275(20)42618-5 Baggio, 1986, Long term effect of fenofibrate on lipoprotein level and composition in different types of genetic hyperlipidemias, Pharmac. Res. Commun., 18, 471, 10.1016/0031-6989(86)90167-0 Balfour, 1990, Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia, Drugs, 40, 260, 10.2165/00003495-199040020-00007 Ballantyne, 1989, Effects of cyclosporin therapy on plasma lipoprotein levels, J. Am. Med. Assoc., 262, 53, 10.1001/jama.1989.03430010065032 Bjornsson, 1979, Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction, J. Pharmac. exp. Ther., 210, 316 Bjornsson, 1979, Effects of clofibrate and warfarin alone and in combination on the disposition of vitamin K1, J. Pharmac. exp. Ther., 210, 322 Blane, 1987, Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives, Am. J. Med., 83, 26, 10.1016/0002-9343(87)90868-0 Brown, 1990, Drugs used in the treatment of hyperlipoproteinemias, 886 Brown, 1986, Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia, Arteriosclerosis, 6, 670, 10.1161/01.ATV.6.6.670 Canzler, 1980, Lowering effect of fenofibrate (Procetofene) on lipoproteins in different types of hyperlipoproteinemias, Artery, 8, 171 Conte-Camerino, 1988, Enantiomers of clofibric acid analogs have opposite actions on rat skeletal muscle chloride channels, Pflügers Arch., 413, 105, 10.1007/BF00581238 Desager, 1980, Uricosuric effect of fenofibrate in healthy volunteers, J. clin. Pharmac., 20, 560, 10.1002/j.1552-4604.1980.tb01670.x De Sante, 1979, The effect of colestipol hydrochloride on the bioavailability and pharmacokinetics of clofibrate, J. clin. Pharmac., 19, 721, 10.1002/j.1552-4604.1979.tb01642.x DeSilva, 1979, Metformin and clofibrate in maturity-onset diabetes mellitus: advantages of combined treatment, Diabetes Metab., 5, 223 Dujovne, 1971, Changes in liver and spleen scans of patients during treatment with two hypolipidemic drugs, Radiology, 98, 682, 10.1148/98.3.682 Eastman, 1973, Warfarin dosage influenced by clofibrate plus age, Lancet, i, 1450 Feller, 1987, Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers, J. med. Chem., 30, 1265, 10.1021/jm00391a001 Ferrari, 1976, Potentiation of hypoglycemic response to intravenous tolbutamide by clofibrate, New Engl. J. Med., 294, 1184, 10.1056/NEJM197605202942120 Ferrari, 1978, Effect of short-term clifibrate on glucose metabolism and insulin secretion in patients with mild maturity-onset diabetes mellitus, Biomedicine, 29, 133 Forland, 1990, Apparent reduced absorption of gemfibrozil when given with colestipol, J. clin. Pharmac., 30, 29, 10.1002/j.1552-4604.1990.tb03434.x Fournel, 1983, Comparative study of four hypolipidaemic agents on the activity of drug-metabolizing enzymes in rat liver microsomes, Int. J. clin. Pharmac. Res., 3, 431 Frick, 1987, Helsinki heart study: primary prevention trial with gemfibrozil in middle aged men with dyslipidemia, New Engl. J. Med., 317, 1237, 10.1056/NEJM198711123172001 Gibson, 1982, Cytochrome P-450 induction by clofibrate. Purification and properties of a hepatic cytochrome P-450 relatively specific for the 12- and 11-hydroxylation of dodecanoic acid (lauric acid), Biochem. J., 203, 161, 10.1042/bj2030161 Goupille, 1991, Hyperlipidemies et manifestations osteoarticulaires, Rev. Med. Interne, 12, 146, 10.1016/S0248-8663(05)81380-3 Gut, 1980, Changes in indications for drugs, Rev. Prat., 30, 265 Hamberger, 1986, In vitro binding study of gemfibrozil to human serum proteins and erythrocytes: Interactions with other drugs, Int. J. clin. Pharmac. Res., 6, 441 Harvengt, 1980, Lack of pharmacokinetic interaction of colestipol and fenofibrate in volunteers, Eur. J. clin. Pharmac., 17, 459, 10.1007/BF00570164 Harvengt, 1980, Hypolipidemic and hypo-uricemic actions of fenofibrate in various types of hyperlipoproteinemias, Artery, 7, 73 Houin, 1978, Clofibrate and enzymatic induction in man, Int. J. clin. Pharmac. Biopharm., 16, 150 Huffman, 1976, The interaction between halofenate and propranolol, Clin. Pharmac. Ther., 19, 807, 10.1002/cpt1976196807 Hunninghake, 1987, Effect of fibric acid derivatives on blood lipid and lipoprotein levels, Am. J. Med., 83, 44, 10.1016/0002-9343(87)90870-9 Hunninghake, 1981, Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia, Metabolism, 30, 610, 10.1016/0026-0495(81)90141-4 Inoue, 1980, Comparative study of human intestinal and hepatic esterases as related to enzymatic properties and hydrolizing activity for ester-type drugs, Jap. J. Pharmac., 30, 529, 10.1254/jjp.30.529 Kasiske, 1991, The adverse impact of cyclosporine on serum lipids in renal transplant recipients, Am. J. Kidney Dis., 17, 700, 10.1016/S0272-6386(12)80355-6 Klosiewitz-Latoszek, 1991, Comparative studies on the influence of different fibrates on serum lipoproteinsn endogenous hyperlipoproteinaemia, Eur. J. clin. Pharmac., 40, 33, 10.1007/BF00315136 Knauf, 1990, Gemfibrozil absorption and elimination in kidney and liver disease, Klin. Wochenschr., 68, 692, 10.1007/BF01667018 Koch-Weser, 1971, Drug interactions with coumarin anticoagulants (second of two parts), New Engl. J. Med., 285, 547, 10.1056/NEJM197109022851005 Magarian, 1991, Gemfibrozil-induced myopathy, Arch. Intern. Med., 151, 1873, 10.1001/archinte.1991.00400090143027 Malmendier, 1985, Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia, Atherosclerosis, 55, 161, 10.1016/0021-9150(85)90095-4 Meffin, 1983, A renal mechanism for the clofibric acid-probenecid interactions, J. Pharmac. exp. Ther., 227, 739 Miners, 1984, Gender and oral contraceptive steroids as determinants of drug glucuronidation: Effects on clofibric acid elimination, Br. J. clin. Pharmac., 18, 240, 10.1111/j.1365-2125.1984.tb02461.x Odegaard, 1985, Drugs affecting lipid metabolism, 10.1016/S0378-6080(85)80050-7 Olivier, 1982, Effect of clofibrate on insulin release from rat islets of langerhans, Horm. Metab. Res., 14, 276, 10.1055/s-2007-1018992 Olsson, 1982, Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia, Atherosclerosis, 42, 229, 10.1016/0021-9150(82)90153-8 O'Reilly, 1987, Warfarin metabolism and drug-drug interactions, Adv. Exp. med. Biol., 214, 205 O'Reilly, 1972, Studies on the interaction of warfarin and clofibrate in man, Thromb. Diath. Haemorrh., 37, 309 Pierce, 1990, Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy, J. Am. med. Ass., 264, 71, 10.1001/jama.1990.03450010075034 Pond, 1975, The effects of allopurinol and clofibrate on the elimination of coumarin anticoagulants in man, Aust. N.Z. J. Med., 5, 324, 10.1111/j.1445-5994.1975.tb03266.x Raine, 1988, Adverse impact of cyclosporin on plasma cholesterol in renal transplant recipients, Nephrol. Dial. Transplant., 3, 458, 10.1093/oxfordjournals.ndt.a091698 Rimon, 1984, Clofibrate-induced muscular syndrome: case report with ultrastructural findings and review of the literature, Israel J. Med. Sci., 20, 1082 Roberts, 1989, Safety of fenofibrate—US and worldwide experience, Cardiology, 76, 169, 10.1159/000174488 Rosenberg, 1984, Antihyperlipidemics, 143 Rouffy, 1985, Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B, Atherosclerosis, 54, 273, 10.1016/0021-9150(85)90121-2 Schorn, 1991, Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients, Transplant Int., 5, 92, 10.1111/j.1432-2277.1991.tb01955.x Schwandt, 1991, Fibrates and triglyceride metabolism, Eur. J. clin. Pharmac., 40, S41, 10.1007/BF03216288 Serlin, 1983, Drug interactions with warfarin, Drugs, 25, 610, 10.2165/00003495-198325060-00004 Sirtori, 1985, Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients, Eur. J. Pharmac., 28, 619, 10.1007/BF00607904 Sirtori, 1992, Tolerability of fibric acids. Comparative data and biochemical bases, Pharmac. Res., 26, 243, 10.1016/1043-6618(92)90212-T Smith, 1991, HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine interaction and mechanism studies, J. Pharmac. exp. Ther., 257, 1225 Smith, 1986, Oral contraceptive opposition to hypercholesterolaemic action of clofibrate, Lancet, i, 750 Smith, 1991, HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine a interaction and mechanism studies, J. Pharmac. exp. Ther., 257, 1225 Solomon, 1973, Massive hemorrhage and death during treatment with clofibrate and warfarin, N.Y. State J. Med., 73, 2002 Steiner, 1991, A comparative review of the adverse effects of treatments for hyperlipidaemia, Drug-Saf., 6, 118, 10.2165/00002018-199106020-00003 Taylor, 1977, Clofibrate increases lipoprotein-lipase activity in adipose tisue of hypertriglyceridaemic patients, Lancet, ii, 1106, 10.1016/S0140-6736(77)90548-7 Tesone, 1985, Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia, Curr. Med. Res. Opin., 9, 650, 10.1185/03007998509109647 Todd, 1988, Gemfibrozil: a review of its pharmadodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia, Drugs, 36, 314, 10.2165/00003495-198836030-00004 Veenendaal, 1981, Probenecid-clofibrate interaction, Clin. Pharmac. Ther., 29, 351, 10.1038/clpt.1981.48 Vogelberg, 1982, The influence of clofibrate on glucose metabolism in diabetes mellitus without endogenous hypertriglyceridemia (author's transl.), Arzeim. Forsch., 32, 413 Vogelberg, 1980, Der Einflub von Clofibrat auf erhohte Serumlaktatspiegel bei mit Biguaniden behandelten Diabetikern, Drug Res., 30, 683 Webb, 1992, Lipid and lipoprotein (a) concentrations in renal transplant patients, Nephrol. Dial. Transplant., 7, 636, 10.1093/ndt/7.7.636 Webb, 1993, Does cyclosporin increase lipoprotein (a) concentrations in renal transplant recipients?, Lancet, 341, 268, 10.1016/0140-6736(93)92616-2 Weisweiler, 1988, Effects of bezafibrate and gemfibrozil on serum lipoproteins in primary hypercholesterolemia, Arzneim. Forsch., 38, 925 Weisweiler, 1986, Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia, Eur. J. clin. Pharmac., 30, 191, 10.1007/BF00614301 Williams, 1976, Effect of concomitantly administered drugs on the control of long term anticoagulant theory, Q. J. Med., 45, 63 Yokoyama, 1988, A little more information about aggravation of probucol-induced HDL-reduction by clofibrate, Atherosclerosis, 70, 179, 10.1016/0021-9150(88)90114-1 Zimetbaum, 1991, Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins, J. clin. Pharmac., 31, 25, 10.1002/j.1552-4604.1991.tb01883.x Zini, 1983, Binding of clometacin to human serum albumin. Interactions with clofibrate, indomethacin, salicylic acid and warfarin, Biochem. Pharmac., 32, 2909, 10.1016/0006-2952(83)90395-7